13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

  
14 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04480853
(ClinicalTrials.gov)
October 12, 202017/7/2020Safety and Efficacy Study of Fingolimod in Taiwanese Adults (= 20years) With Relapsing Remitting Multiple SclerosisA 12-month, Prospective, Multi-center Post-authorization Commitment (PAC) Study Monitoring Safety in Adult Patients With Relapsing-remitting Multiple Sclerosis Newly Initiated on Gilenya (Fingolimod) in Taiwan (SPRING)Multiple SclerosisDrug: FingolimodNovartis PharmaceuticalsNULLRecruiting20 YearsN/AAll30Phase 4Taiwan
2NCT03283397
(ClinicalTrials.gov)
March 26, 201912/9/2017A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMSA Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Neuropeptide Combination of Metenkefalin and Tridecactide (EK-12) in Comparison to Interferon Beta-1a (REBIF®) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Multiple Sclerosis, Relapsing-RemittingDrug: EK-12;Drug: INF beta-1aBosnalijek D.DMonitorCRORecruiting18 Years55 YearsAll400Phase 3Turkey
3NCT03244696
(ClinicalTrials.gov)
November 2, 20177/8/2017Behavior and Activity Monitoring in MSBehavior and Activity Monitoring in Multiple SclerosisRelapsing-Remitting Multiple SclerosisBehavioral: Step Tracking;Behavioral: Water TrackingOhio State UniversityNational Multiple Sclerosis SocietyActive, not recruiting30 Years59 YearsAll87N/AUnited States
4NCT02901106
(ClinicalTrials.gov)
May 23, 20177/9/2016Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarateMonitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate SURV-SEPMultiple Sclerosis, Relapsing-RemittingDrug: Dimethyl fumarateFondation Ophtalmologique Adolphe de RothschildNULLTerminated18 YearsN/AAll11Phase 4France
5NCT02343159
(ClinicalTrials.gov)
February 28, 20159/1/2015Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients.Multiple SclerosisDrug: dimethyl fumarate;Device: Medication Event Monitoring System (MEMS);Behavioral: Adherence counselingBiogenNULLTerminated18 Years65 YearsAll84Phase 4United States
6NCT02335450
(ClinicalTrials.gov)
February 12, 20157/1/2015Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case SeriesTheory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case SeriesMultiple SclerosisBehavioral: Motivational Interviewing;Device: Wristband physical activity monitorOakland UniversityNULLCompleted19 YearsN/AAll5N/AUnited States
7EUCTR2012-000411-91-DE
(EUCTR)
13/02/201304/12/2012Monitoring natural killer cells in multiple sclerosis patients treated with fingolimodMonitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial - NKZellen-Version1.0 relapsing-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Gilenya®
Product Name: Gilenya®
Product Code: Gilenya®
INN or Proposed INN: Fingolimod
Other descriptive name: FINGOLIMOD
Charité - Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
40Phase 4Germany
8NCT01624714
(ClinicalTrials.gov)
September 201218/6/2012Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced SubjectsPhase I Trial Monitoring Efficacy and Safety in Treatment of Alemtuzumab Naive Subjects and Data Collecting and Monitoring of Alemtuzumab Experienced Subjects With Refractory Multiple SclerosisMultiple SclerosisDrug: Alemtuzumab;Drug: Alemtuzumab immunotherapySamuel Forrester Hunter, MD, PhDNULLActive, not recruiting18 Years75 YearsBoth60Phase 1United States
9NCT01442194
(ClinicalTrials.gov)
August 1, 201121/8/2011Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying TherapiesLong-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying TherapyMultiple SclerosisDrug: other disease-modifying therapy;Drug: FingolimodNovartis PharmaceuticalsNULLCompletedN/AN/AAll3076United States;Argentina;Australia;Canada;Chile;Mexico;Puerto Rico
10EUCTR2011-001956-12-CZ
(EUCTR)
25/05/201104/05/2011Biological Efficacy of Interferon ß Therapy in Patients with Multiple SclerosisMonitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis. To correlate bioactivity of IFNß reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNß depending on NAbs statusNAbs positive cohorts will be correlated NAbs titer with level of MxA expression, respectively if the MxA decrease is not preceding NAbs positivity. The MxA induction test will be tested.Trade Name: Avonex®
Product Name: Avonex®
Product Code: EU/1/97/033/002
Trade Name: Betaferon®
Product Name: Betaferon®
Product Code: EU/1/95/003/005-010
Trade Name: Rebif 22®
Product Name: Rebif 22®
Product Code: EU/1/98/063/001-003
Trade Name: Rebif 44®
Product Name: Rebif 44®
Product Code: EU/1/98/063/004-006
Trade Name: Extavia®
Product Name: Extavia®
Product Code: EU/1/08/454/001-002, EU/1/08/454/005-007
University Hospital MotolNULLNot RecruitingFemale: yes
Male: yes
Phase 4Czech Republic
11EUCTR2010-023678-38-IT
(EUCTR)
20/04/201102/02/2011High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - NDHigh-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND patients with multiple sclerosis
MedDRA version: 9.1;Level: PT;Classification code 10028245
Trade Name: MANTADAN*20CPR 100MG
INN or Proposed INN: Amantadine
Trade Name: AMPYRA
INN or Proposed INN: Ampyra
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABORNULLNot RecruitingFemale: yes
Male: yes
Italy
12NCT01281657
(ClinicalTrials.gov)
February 201119/1/2011Long Term Study of Fingolimod in MS Patients From the FTY Clinical ProgramA Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development ProgramMultiple SclerosisDrug: fingolimodNovartisNULLCompleted18 YearsN/ABoth64N/AUnited States;Canada
13NCT01142453
(ClinicalTrials.gov)
May 200510/6/2010An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) PatientsTherapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in MS Patients. Case Series for Adjustment of Treatment Strategy and Its MonitoringRelapsing-Remitting Multiple SclerosisDrug: Interferon beta 1aMerck KGaAGesellschaft für Therapieforschung mbHCompletedN/AN/ABoth231N/ANULL
14NCT00203021
(ClinicalTrials.gov)
March 26, 199412/9/2005Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and EffectivenessOpen Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With CopaxoneRelapsing-Remitting Multiple SclerosisDrug: Glatiramer acetateTeva Branded Pharmaceutical Products R&D, Inc.NULLCompleted18 YearsN/AAll208Phase 4United States